Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 14/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.39 |
| ▸ | GSK3B | P49841 | 13/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785659 | 0.92 | DYRK1A (0.37) | WNT1DYRK1AGSK3BBRAFBRD4 | |
| SCHEMBL16776376 | 0.85 | POLB (0.41) | BRAFCNR2GRM5 | |
| SCHEMBL16776377 | 0.82 | MPL (0.41) | CNR2GRM5 | |
| SCHEMBL16776386 | 0.81 | IMPDH2 (0.36) | WNT1DYRK1AGSK3BBRAFBRD4 | |
| SCHEMBL19670550 | 0.79 | RHOA (0.39) | WNT1DYRK1AGSK3BBRAFRHOA | |
| SCHEMBL17618833 | 0.78 | RHOA (0.38) | WNT1DYRK1AGSK3BBRAFCREBBP | |
| SCHEMBL16776409 | 0.78 | WNT1 (0.39) | WNT1DYRK1AGSK3BBRAFBRD4 | |
| SCHEMBL16776399 | 0.77 | CREBBP (0.42) | DYRK1AGSK3BBRAFBRD4CREBBP | |
| SCHEMBL16776380 | 0.77 | BRAF (0.46) | BRAFBRD4CREBBPRHOA | |
| SCHEMBL16776357 | 0.77 | BRAF (0.40) | WNT1DYRK1AGSK3BBRAFRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WNT1 3363/4885DYRK1A 2623/4885GSK3B 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.